MRE11A and SKP2 Genes Are Associated with the Increased Cytotoxicity Induced by the Synergistic Effects of Cisplatin and Gemcitabine in Bladder Cancer Cells

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2014 Mar 22

PMID 24652204

Citations 4

Authors

Glenda Nicioli da Silva

Elaine Aparecida de Camargo

Andre Luiz Ventura Savio

Daisy Maria Favero Salvadori

Affiliations

Soon will be listed here.

Abstract

The combination of gemcitabine and cisplatin has been shown previously to elicit a synergistic therapeutic effect on bladder cancer cell lines and result in reduced cell survival. However, the precise mechanism by which cells die has not been elucidated. Cell cycle-related genes are the predominant targets of chemotherapeutic protocols. Therefore, molecular biomarkers that are predictive of therapeutic outcomes associated with tumor sensitivity might be important for optimal treatment protocol selection. The aim of this study was to investigate the changes in gene expression in cell cycle-related genes that were induced by cisplatin, gemcitabine or a combined treatment using both agents in a low-grade urinary bladder transitional carcinoma cell line (RT4). The following three treatment protocols were used: 1.0 μM cisplatin, 1.56 μM gemcitabine and a combination of 1.0 μM cisplatin and 1.56 μM gemcitabine. Cytometry and morphology analysis (by phase-contrast photomicrography) were performed in addition to pathway-specific gene expression analysis using quantitative RT-PCR gene arrays. The following results were observed after 1.0 μM cisplatin treatment: (1) a decrease in cell number, (2) an increased percentage of scattered cells and (3) downregulated expression of genes related to cell cycle arrest, G1/S-to-mitotic cell cycle transition, DNA repair, apoptosis, transcription and mitosis. Treatment with 1.56 μM gemcitabine, or with both drugs simultaneously, induced the following effects: (1) a decrease in cell number, (2) an increased percentage of scattered and elongated cells, (3) the modulation of genes that are predominantly involved in DNA repair and (4) a significant upregulation of genes related to cell cycle arrest. Reduced cell density was observed after the combined treatment compared to the two other single-agent protocols. The downregulation of MRE11A and SKP2 was observed only in cells subjected to the combined treatment. In conclusion, cisplatin, gemcitabine and the combination of both drugs elicited distinct toxicogenomic effects in the RT4 bladder transitional carcinoma cell line, although disruptions in the expression of cell cycle control-related genes and other pathways responsible for cell survival were observed for all of the protocols. MRE11A and SKP2 downregulation appeared to be responsible for the synergistic therapeutic effects elicited by cisplatin and gemcitabine.

Citing Articles

TRIM24 is critical for the cellular response to DNA double-strand breaks through regulating the recruitment of MRN complex.

Wang Y, Yao Y, Wei Q, Long S, Chen Y, Xie J Oncogene. 2022; 42(8):586-600.

PMID: 36550358 DOI: 10.1038/s41388-022-02580-8.

MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment.

Bian L, Meng Y, Zhang M, Li D Mol Cancer. 2019; 18(1):169.

PMID: 31767017 PMC: 6878665. DOI: 10.1186/s12943-019-1100-5.

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.

Sakamoto Y, Yamagishi S, Okusaka T, Ojima H Cells. 2019; 8(9).

PMID: 31484399 PMC: 6770112. DOI: 10.3390/cells8091026.

Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.

Silva G, Filoni L, Salvadori M, Salvadori D Pathol Oncol Res. 2017; 24(2):407-417.

PMID: 28577130 DOI: 10.1007/s12253-017-0255-x.

References

Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T . Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005; 11(7):2625-36. DOI: 10.1158/1078-0432.CCR-04-1988. View

Bellmunt J, Albiol S, de Olano A, Pujadas J, Maroto P . Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol. 2006; 17 Suppl 5:v113-7. DOI: 10.1093/annonc/mdj964. View

Vilar E, Bartnik C, Stenzel S, Raskin L, Ahn J, Moreno V . MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011; 71(7):2632-42. PMC: 3407272. DOI: 10.1158/0008-5472.CAN-10-1120. View

Goncalves E, Ventura C, Yano T, Macedo M, Genari S . Morphological and growth alterations in Vero cells transformed by cisplatin. Cell Biol Int. 2006; 30(6):485-94. DOI: 10.1016/j.cellbi.2005.12.007. View

Rink M, Cha E, Green D, Hansen J, Robinson B, Lotan Y . Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep. 2012; 13(2):122-35. DOI: 10.1007/s11934-012-0237-1. View

Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J . Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene. 2004; 24(8):1396-402. DOI: 10.1038/sj.onc.1208313. View

Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F . Role of gemcitabine in cancer therapy. Future Oncol. 2006; 1(1):7-17. DOI: 10.1517/14796694.1.1.7. View

Kraemer K, Schmidt U, Fuessel S, Herr A, Wirth M, Meye A . Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. Int J Cancer. 2006; 119(6):1276-84. DOI: 10.1002/ijc.21975. View

Silva G, de Camargo E, Salvadori D . Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes. Mol Biol Rep. 2012; 39(12):10373-82. DOI: 10.1007/s11033-012-1916-1. View

10.

Cordon-Cardo C . Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl. 2008; (218):154-65. DOI: 10.1080/03008880802291915. View

11.

Weis E, Schoen H, Victor A, Spix C, Ludwig M, Schneider-Raetzke B . Reduced mRNA and protein expression of the genomic caretaker RAD9A in primary fibroblasts of individuals with childhood and independent second cancer. PLoS One. 2011; 6(10):e25750. PMC: 3185005. DOI: 10.1371/journal.pone.0025750. View

12.

Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Soto M . Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov. 2008; 1(1):39-53. DOI: 10.2174/157489206775246430. View

13.

Shigechi T, Tomida J, Sato K, Kobayashi M, Eykelenboom J, Pessina F . ATR-ATRIP kinase complex triggers activation of the Fanconi anemia DNA repair pathway. Cancer Res. 2012; 72(5):1149-56. DOI: 10.1158/0008-5472.CAN-11-2904. View

14.

Sun T, Yang W, Liu J, Shen P . Modeling the basal dynamics of p53 system. PLoS One. 2011; 6(11):e27882. PMC: 3218058. DOI: 10.1371/journal.pone.0027882. View

15.

Rabiau N, Kossai M, Braud M, Chalabi N, Satih S, Bignon Y . Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol. 2010; 34(2):200-6. DOI: 10.1016/j.canep.2009.12.018. View

16.

de Camargo E, Silva G, Gobette C, de Castro Marcondes J, Salvadori D . No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine. Asian Pac J Cancer Prev. 2013; 14(10):5941-8. DOI: 10.7314/apjcp.2013.14.10.5941. View

17.

Hsieh H, Shieh J, Chen C, Pan M, Yang S, Lin S . Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells. Br J Pharmacol. 2012; 166(7):2095-108. PMC: 3402774. DOI: 10.1111/j.1476-5381.2012.01921.x. View

18.

Missiaglia E, Donadelli M, Palmieri M, Crnogorac-Jurcevic T, Scarpa A, Lemoine N . Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene. 2005; 24(1):199-211. DOI: 10.1038/sj.onc.1208018. View

19.

Martin D, Bertino J, Koutcher J . ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Cancer Res. 2001; 60(24):6776-83. View

20.

Chen R, Feng C, Xu Y . Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res. 2011; 39(2):533-40. DOI: 10.1177/147323001103900222. View